Shunqiang Li, PhD

Primary Academic Title

Associate Professor of Medicine, Division of Oncology, WashU Medicine

Research Interest

1) Establishment and characterization of patient-derived xenograft (PDX) models, 2) PDX-based preclinical testing of new anticancer drugs and treatments, 3) Application of PDX models to cancer translation research, including tumorigenesis, resistance, metastasis, and biomarker, 4) HAMLET core service

Education

1999: PhD, pharmacology, Chinese Academy of Medical Sciences and Peking Union Medical College, P.R. China

Training

1999 - 2002: Postdoctoral research, Fred Hutchinson Cancer Research Center, Seattle
2002 - 2004: Postdoctoral research, University of North Carolina at Chapel Hill

Selected Research Publications

NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

Zheng ZY, Chen A, Jaehnig EJ, [...] Li S, [...] Chang EC
Sci Transl Med 2025

Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB-Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer.

Zhou S, Zhang Y, Belmar J, [...] Li S, Zhu W
Cancer Res 2025

PCO25-209: Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model.

Gil M, Yu T, Alderson M, [...] Li S, Opyrchal M
J Natl Compr Canc Netw 2025

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer.

Zhang Y, Zhou S, Kai Y, [...] Li S, Zhu W
Nat Commun 2024

A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.

White BS, Woo XY, Koc S, [...] Li S, [...] Chuang JH
Cancer Res 2024

Development of a [89Zr]Zr-labeled Human Antibody using a Novel Phage-displayed Human scFv Library.

Singh AK, Lewis CD, Boas CAWV, [...] Li S, [...] Hallahan DE
Clin Cancer Res 2024

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.

Wu Y, Chen S, Yang X, [...] Li S, [...] Chen F
Cancer Res 2023

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.

Gou X, Kim BJ, Anurag M, [...] Li S, [...] Ellis MJ
Cancer Res 2023

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.

Cheng X, Sun Y, Highkin M, [...] Li S, [...] Bose R
Cancer Res 2023

View All Publications